BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Additional Phase III data

Data from a subset of 348 patients aged 65-75 years with newly diagnosed MM in the double-blind, international Phase III MM-015 trial showed that the Revlimid plus melphalan and prednisone followed by Revlimid (MPR-R) and the Revlimid plus melphalan and prednisone followed by placebo (MPR) arms each significantly improved median PFS, the primary endpoint, vs....

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >